Search results
Results from the WOW.Com Content Network
Novavax successfully developed a COVID-19 vaccine that is currently its only product on the market. The company has been working on two other candidates. One is an investigational influenza vaccine.
Shares of vaccine stocks Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX), and BioNTech SE (NASDAQ: BNTX) rallied this week, appreciating 23.4%, 16.4%, and 9.3%, respectively, through Thursday ...
If the omicron variant of Covid-19 was supposed to be a tide that lifted all vaccine stocks, someone forgot to tell Novavax (NASDAQ:NVAX) investors. Since the close of the markets on Nov. 26, NVAX ...
An hour before the market closed Thursday, as news reports of Trump’s choice began trickling out, Covid-19 vaccine maker Moderna dipped as much as 6%, and Pfizer fell almost 2%.
The news got even better last week, when the UK drug regulatory commission MHRA authorized Pfizer and BioNTech to distribute their Covid-19 mRNA vaccine for emergency use and the first doses could ...
The company — which expects its 2023 revenus to be at least $6 billion — reported $1.8 billion in COVID-19 vaccine sales in the third quarter and $3.9 billion through Q3.
Although the FDA is yet to approve a drug or treatment for COVID-19, companies have already started ramping up manufacturing lines to meet global demand if any of the experimental vaccines succeed.
As the omicron variant picks up speed, investors are turning to vaccine stocks that could potentially profit. The U.S. is currently averaging 121,107 new Covid-19 cases per day and showing no ...